Which has preferable earnings & valuation, MEDP or EHC?

Encompass Health has higher revenue and earnings than Medpace. Encompass Health is trading at a lower price-to-earnings ratio than Medpace, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Medpace $2.53B 6.78 $451.12M $17.06 36.02 Encompass Health $5.94B 2.03 $566.20M $6.14 19.94

Does the media prefer MEDP or EHC?

In the previous week, Medpace had 8 more articles in the media than Encompass Health. MarketBeat recorded 25 mentions for Medpace and 17 mentions for Encompass Health. Medpace's average media sentiment score of 1.13 beat Encompass Health's score of 1.12 indicating that Medpace is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Medpace 19 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Encompass Health 11 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Which has preferable valuation & earnings, ELV or MEDP?

Elevance Health has higher revenue and earnings than Medpace. Elevance Health is trading at a lower price-to-earnings ratio than Medpace, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Elevance Health $199.13B 0.43 $5.66B $22.50 17.64 Medpace $2.53B 6.78 $451.12M $17.06 36.02

Is ELV or MEDP more profitable?

Medpace has a net margin of 17.67% compared to Elevance Health's net margin of 2.47%. Medpace's return on equity of 110.15% beat Elevance Health's return on equity. Company Net Margins Return on Equity Return on Assets Elevance Health 2.47% 14.64% 5.22% Medpace 17.67% 110.15% 24.84%

Does the media prefer ELV or MEDP?

In the previous week, Elevance Health had 8 more articles in the media than Medpace. MarketBeat recorded 33 mentions for Elevance Health and 25 mentions for Medpace. Elevance Health's average media sentiment score of 1.64 beat Medpace's score of 1.13 indicating that Elevance Health is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Elevance Health 31 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Medpace 19 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has higher valuation and earnings, MEDP or HIMS?

Medpace has higher revenue and earnings than Hims & Hers Health. Hims & Hers Health is trading at a lower price-to-earnings ratio than Medpace, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Medpace $2.53B 6.78 $451.12M $17.06 36.02 Hims & Hers Health $2.35B 3.25 $128.37M -$0.63 N/A

Does the media prefer MEDP or HIMS?

In the previous week, Hims & Hers Health had 4 more articles in the media than Medpace. MarketBeat recorded 29 mentions for Hims & Hers Health and 25 mentions for Medpace. Medpace's average media sentiment score of 1.13 beat Hims & Hers Health's score of 0.21 indicating that Medpace is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Medpace 19 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Hims & Hers Health 8 Very Positive mention(s) 4 Positive mention(s) 12 Neutral mention(s) 3 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has better earnings & valuation, IQV or MEDP?

IQVIA has higher revenue and earnings than Medpace. IQVIA is trading at a lower price-to-earnings ratio than Medpace, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio IQVIA $16.31B 2.57 $1.36B $8.06 31.57 Medpace $2.53B 6.78 $451.12M $17.06 36.02

Is IQV or MEDP more profitable?

Medpace has a net margin of 17.67% compared to IQVIA's net margin of 8.10%. Medpace's return on equity of 110.15% beat IQVIA's return on equity. Company Net Margins Return on Equity Return on Assets IQVIA 8.10% 30.25% 6.54% Medpace 17.67% 110.15% 24.84%

Does the media prefer IQV or MEDP?

In the previous week, Medpace had 8 more articles in the media than IQVIA. MarketBeat recorded 25 mentions for Medpace and 17 mentions for IQVIA. IQVIA's average media sentiment score of 1.26 beat Medpace's score of 1.13 indicating that IQVIA is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment IQVIA 14 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Medpace 19 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer A or MEDP?

In the previous week, Agilent Technologies had 6 more articles in the media than Medpace. MarketBeat recorded 31 mentions for Agilent Technologies and 25 mentions for Medpace. Agilent Technologies' average media sentiment score of 1.54 beat Medpace's score of 1.13 indicating that Agilent Technologies is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Agilent Technologies 28 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Medpace 19 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Medpace (MEDP) Competitors

$614.52 +6.25 (+1.03%)

As of 10:48 AM Eastern

Compare

MEDP vs. EHC, ELV, HIMS, IQV, and A

Should you buy Medpace stock or one of its competitors? Medpace's main competitors and comparable companies include Encompass Health (EHC), Elevance Health (ELV), Hims & Hers Health (HIMS), IQVIA (IQV), and Agilent Technologies (A). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare" sector.

How does Medpace compare to Encompass Health?

Medpace (NASDAQ:MEDP) and Encompass Health (NYSE:EHC) are both large-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, analyst recommendations, media sentiment, profitability, valuation, earnings, risk and dividends.

In the previous week, Medpace had 8 more articles in the media than Encompass Health. MarketBeat recorded 25 mentions for Medpace and 17 mentions for Encompass Health. Medpace's average media sentiment score of 1.13 beat Encompass Health's score of 1.12 indicating that Medpace is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Medpace	19 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Encompass Health	11 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Medpace has a beta of 1.15, meaning that its share price is 15% more volatile than the broader market. Comparatively, Encompass Health has a beta of 0.72, meaning that its share price is 28% less volatile than the broader market.

Medpace currently has a consensus price target of $584.18, suggesting a potential downside of 4.94%. Encompass Health has a consensus price target of $148.71, suggesting a potential upside of 21.47%. Given Encompass Health's stronger consensus rating and higher possible upside, analysts clearly believe Encompass Health is more favorable than Medpace.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Medpace	0 Sell rating(s)	10 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.23
Encompass Health	0 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	3.00

Medpace has a net margin of 17.67% compared to Encompass Health's net margin of 10.01%. Medpace's return on equity of 110.15% beat Encompass Health's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Medpace	17.67%	110.15%	24.84%
Encompass Health	10.01%	18.08%	8.22%

Encompass Health has higher revenue and earnings than Medpace. Encompass Health is trading at a lower price-to-earnings ratio than Medpace, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Medpace	$2.53B	6.78	$451.12M	$17.06	36.02
Encompass Health	$5.94B	2.03	$566.20M	$6.14	19.94

78.0% of Medpace shares are held by institutional investors. Comparatively, 97.3% of Encompass Health shares are held by institutional investors. 20.5% of Medpace shares are held by insiders. Comparatively, 1.8% of Encompass Health shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Summary

Medpace beats Encompass Health on 10 of the 17 factors compared between the two stocks.

How does Medpace compare to Elevance Health?

Elevance Health (NYSE:ELV) and Medpace (NASDAQ:MEDP) are both large-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, risk, profitability, institutional ownership, analyst recommendations, dividends, media sentiment and earnings.

Elevance Health presently has a consensus price target of $440.90, suggesting a potential upside of 11.09%. Medpace has a consensus price target of $584.18, suggesting a potential downside of 4.94%. Given Elevance Health's stronger consensus rating and higher probable upside, research analysts plainly believe Elevance Health is more favorable than Medpace.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Elevance Health	0 Sell rating(s)	8 Hold rating(s)	15 Buy rating(s)	0 Strong Buy rating(s)	2.65
Medpace	0 Sell rating(s)	10 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.23

Elevance Health has higher revenue and earnings than Medpace. Elevance Health is trading at a lower price-to-earnings ratio than Medpace, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Elevance Health	$199.13B	0.43	$5.66B	$22.50	17.64
Medpace	$2.53B	6.78	$451.12M	$17.06	36.02

In the previous week, Elevance Health had 8 more articles in the media than Medpace. MarketBeat recorded 33 mentions for Elevance Health and 25 mentions for Medpace. Elevance Health's average media sentiment score of 1.64 beat Medpace's score of 1.13 indicating that Elevance Health is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Elevance Health	31 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Medpace	19 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

89.2% of Elevance Health shares are owned by institutional investors. Comparatively, 78.0% of Medpace shares are owned by institutional investors. 0.3% of Elevance Health shares are owned by insiders. Comparatively, 20.5% of Medpace shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Elevance Health has a beta of 0.68, indicating that its stock price is 32% less volatile than the broader market. Comparatively, Medpace has a beta of 1.15, indicating that its stock price is 15% more volatile than the broader market.

Medpace has a net margin of 17.67% compared to Elevance Health's net margin of 2.47%. Medpace's return on equity of 110.15% beat Elevance Health's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Elevance Health	2.47%	14.64%	5.22%
Medpace	17.67%	110.15%	24.84%

Summary

Elevance Health beats Medpace on 9 of the 16 factors compared between the two stocks.

How does Medpace compare to Hims & Hers Health?

Medpace (NASDAQ:MEDP) and Hims & Hers Health (NYSE:HIMS) are both healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their earnings, dividends, risk, profitability, institutional ownership, valuation, analyst recommendations and media sentiment.

Medpace has a net margin of 17.67% compared to Hims & Hers Health's net margin of -5.51%. Medpace's return on equity of 110.15% beat Hims & Hers Health's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Medpace	17.67%	110.15%	24.84%
Hims & Hers Health	-5.51%	-6.51%	-1.20%

Medpace has higher revenue and earnings than Hims & Hers Health. Hims & Hers Health is trading at a lower price-to-earnings ratio than Medpace, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Medpace	$2.53B	6.78	$451.12M	$17.06	36.02
Hims & Hers Health	$2.35B	3.25	$128.37M	-$0.63	N/A

78.0% of Medpace shares are owned by institutional investors. Comparatively, 63.5% of Hims & Hers Health shares are owned by institutional investors. 20.5% of Medpace shares are owned by company insiders. Comparatively, 11.8% of Hims & Hers Health shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Medpace presently has a consensus target price of $584.18, suggesting a potential downside of 4.94%. Hims & Hers Health has a consensus target price of $32.43, suggesting a potential downside of 0.90%. Given Hims & Hers Health's higher possible upside, analysts clearly believe Hims & Hers Health is more favorable than Medpace.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Medpace	0 Sell rating(s)	10 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.23
Hims & Hers Health	1 Sell rating(s)	11 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.19

Medpace has a beta of 1.15, suggesting that its share price is 15% more volatile than the broader market. Comparatively, Hims & Hers Health has a beta of 2.4, suggesting that its share price is 140% more volatile than the broader market.

In the previous week, Hims & Hers Health had 4 more articles in the media than Medpace. MarketBeat recorded 29 mentions for Hims & Hers Health and 25 mentions for Medpace. Medpace's average media sentiment score of 1.13 beat Hims & Hers Health's score of 0.21 indicating that Medpace is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Medpace	19 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Hims & Hers Health	8 Very Positive mention(s)	4 Positive mention(s)	12 Neutral mention(s)	3 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Medpace beats Hims & Hers Health on 12 of the 16 factors compared between the two stocks.

How does Medpace compare to IQVIA?

IQVIA (NYSE:IQV) and Medpace (NASDAQ:MEDP) are both large-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their risk, analyst recommendations, dividends, valuation, profitability, earnings, institutional ownership and media sentiment.

89.6% of IQVIA shares are owned by institutional investors. Comparatively, 78.0% of Medpace shares are owned by institutional investors. 1.7% of IQVIA shares are owned by insiders. Comparatively, 20.5% of Medpace shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

IQVIA currently has a consensus price target of $241.88, indicating a potential downside of 4.93%. Medpace has a consensus price target of $584.18, indicating a potential downside of 4.94%. Given IQVIA's stronger consensus rating and higher probable upside, analysts clearly believe IQVIA is more favorable than Medpace.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
IQVIA	0 Sell rating(s)	3 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.88
Medpace	0 Sell rating(s)	10 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.23

IQVIA has higher revenue and earnings than Medpace. IQVIA is trading at a lower price-to-earnings ratio than Medpace, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
IQVIA	$16.31B	2.57	$1.36B	$8.06	31.57
Medpace	$2.53B	6.78	$451.12M	$17.06	36.02

IQVIA has a beta of 1.18, suggesting that its stock price is 18% more volatile than the broader market. Comparatively, Medpace has a beta of 1.15, suggesting that its stock price is 15% more volatile than the broader market.

In the previous week, Medpace had 8 more articles in the media than IQVIA. MarketBeat recorded 25 mentions for Medpace and 17 mentions for IQVIA. IQVIA's average media sentiment score of 1.26 beat Medpace's score of 1.13 indicating that IQVIA is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
IQVIA	14 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Medpace	19 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Medpace has a net margin of 17.67% compared to IQVIA's net margin of 8.10%. Medpace's return on equity of 110.15% beat IQVIA's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
IQVIA	8.10%	30.25%	6.54%
Medpace	17.67%	110.15%	24.84%

Summary

IQVIA beats Medpace on 9 of the 17 factors compared between the two stocks.

How does Medpace compare to Agilent Technologies?

Agilent Technologies (NYSE:A) and Medpace (NASDAQ:MEDP) are both large-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, earnings, valuation, dividends, media sentiment, risk, profitability and institutional ownership.

In the previous week, Agilent Technologies had 6 more articles in the media than Medpace. MarketBeat recorded 31 mentions for Agilent Technologies and 25 mentions for Medpace. Agilent Technologies' average media sentiment score of 1.54 beat Medpace's score of 1.13 indicating that Agilent Technologies is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Agilent Technologies	28 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Medpace	19 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

78.0% of Medpace shares are owned by institutional investors. 20.5% of Medpace shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Agilent Technologies has a net margin of 19.55% compared to Medpace's net margin of 17.67%. Medpace's return on equity of 110.15% beat Agilent Technologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Agilent Technologies	19.55%	24.33%	12.99%
Medpace	17.67%	110.15%	24.84%

Agilent Technologies has a beta of 1.25, indicating that its stock price is 25% more volatile than the broader market. Comparatively, Medpace has a beta of 1.15, indicating that its stock price is 15% more volatile than the broader market.

Agilent Technologies currently has a consensus price target of $160.24, indicating a potential upside of 2.44%. Medpace has a consensus price target of $584.18, indicating a potential downside of 4.94%. Given Agilent Technologies' stronger consensus rating and higher probable upside, equities research analysts clearly believe Agilent Technologies is more favorable than Medpace.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Agilent Technologies	0 Sell rating(s)	4 Hold rating(s)	13 Buy rating(s)	2 Strong Buy rating(s)	2.89
Medpace	0 Sell rating(s)	10 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.23

Agilent Technologies has higher revenue and earnings than Medpace. Agilent Technologies is trading at a lower price-to-earnings ratio than Medpace, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Agilent Technologies	$6.95B	6.36	$1.30B	$4.98	31.41
Medpace	$2.53B	6.78	$451.12M	$17.06	36.02

Summary

Agilent Technologies beats Medpace on 10 of the 17 factors compared between the two stocks.

Get Medpace News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding MEDP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

MEDP vs. The Competition

Export

Metric	Medpace	Life Sciences Tools & Services Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$17.15B	$9.99B	$7.26B	$12.78B
Dividend Yield	N/A	1.47%	2.55%	10.29%
P/E Ratio	36.02	59.63	269.16	24.14
Price / Sales	6.78	108.45	615.85	97.71
Price / Cash	34.69	26.08	78.23	52.73
Price / Book	39.54	38.11	13.06	6.20
Net Income	$451.12M	$56.67B	$3.46B	$347.71M
7 Day Performance	5.60%	2.56%	1.37%	-0.63%
1 Month Performance	16.40%	8.96%	4.49%	2.13%
1 Year Performance	31.95%	25.36%	27.84%	20.34%

Medpace Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
MEDP Medpace	3.7515 of 5 stars	$614.52 +1.0%	$584.18 -4.9%	+31.6%	$17.15B	$2.53B	36.02	6,200	Positive News
EHC Encompass Health	4.8362 of 5 stars	$121.94 -1.3%	$148.71 +22.0%	-0.1%	$12.19B	$5.94B	19.86	42,000
ELV Elevance Health	4.9175 of 5 stars	$390.69 -2.4%	$440.90 +12.9%	+27.6%	$86.82B	$199.13B	17.36	97,100	Positive News
HIMS Hims & Hers Health	1.8591 of 5 stars	$28.50 +1.2%	$32.43 +13.8%	-26.4%	$6.57B	$2.35B	N/A	2,442	Trending News Insider Trade
IQV IQVIA	4.0596 of 5 stars	$241.09 +1.9%	$241.88 +0.3%	+29.6%	$38.95B	$16.31B	29.91	93,000	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:MEDP) was last updated on 8/20/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Medpace (MEDP) Competitors

MEDP vs. EHC, ELV, HIMS, IQV, and A

How does Medpace compare to Encompass Health?

Summary

How does Medpace compare to Elevance Health?

Summary

How does Medpace compare to Hims & Hers Health?

Summary

How does Medpace compare to IQVIA?

Summary

How does Medpace compare to Agilent Technologies?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MEDP vs. The Competition

Medpace Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Medpace (MEDP) Competitors

MEDP vs. EHC, ELV, HIMS, IQV, and A

How does Medpace compare to Encompass Health?

Does the media prefer MEDP or EHC?

Which has more risk and volatility, MEDP or EHC?

Do analysts rate MEDP or EHC?

Is MEDP or EHC more profitable?

Which has preferable earnings & valuation, MEDP or EHC?

Do insiders & institutionals hold more shares of MEDP or EHC?

Summary

How does Medpace compare to Elevance Health?

Do analysts recommend ELV or MEDP?

Which has preferable valuation & earnings, ELV or MEDP?

Does the media prefer ELV or MEDP?

Do insiders and institutionals hold more shares of ELV or MEDP?

Which has more risk & volatility, ELV or MEDP?

Is ELV or MEDP more profitable?

Summary

How does Medpace compare to Hims & Hers Health?

Is MEDP or HIMS more profitable?

Which has higher valuation and earnings, MEDP or HIMS?

Do institutionals and insiders hold more shares of MEDP or HIMS?

Do analysts prefer MEDP or HIMS?

Which has more volatility & risk, MEDP or HIMS?

Does the media prefer MEDP or HIMS?

Summary

How does Medpace compare to IQVIA?

Do institutionals and insiders believe in IQV or MEDP?

Do analysts prefer IQV or MEDP?

Which has better earnings & valuation, IQV or MEDP?

Which has more volatility and risk, IQV or MEDP?

Does the media prefer IQV or MEDP?

Is IQV or MEDP more profitable?

Summary

How does Medpace compare to Agilent Technologies?

Does the media prefer A or MEDP?

Do institutionals & insiders hold more shares of A or MEDP?

Is A or MEDP more profitable?

Which has more risk and volatility, A or MEDP?

Do analysts prefer A or MEDP?

Which has higher valuation & earnings, A or MEDP?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MEDP vs. The Competition

Medpace Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools